1. Home
  2. SCSC vs GYRE Comparison

SCSC vs GYRE Comparison

Compare SCSC & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ScanSource Inc.

SCSC

ScanSource Inc.

HOLD

Current Price

$58.59

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

N/A

Current Price

$6.69

Market Cap

606.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SCSC
GYRE
Founded
1992
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
606.4M
IPO Year
1997
2004

Fundamental Metrics

Financial Performance
Metric
SCSC
GYRE
Price
$58.59
$6.69
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
$43.00
$17.00
AVG Volume (30 Days)
301.5K
57.4K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
21.33
N/A
EPS
3.64
N/A
Revenue
$3,846,260,000.00
$275,000.00
Revenue This Year
$2.60
$19.88
Revenue Next Year
$4.01
N/A
P/E Ratio
$15.99
N/A
Revenue Growth
7.79
N/A
52 Week Low
$33.76
$5.44
52 Week High
$66.78
$9.42

Technical Indicators

Market Signals
Indicator
SCSC
GYRE
Relative Strength Index (RSI) 56.89 53.40
Support Level $49.77 $6.44
Resistance Level $59.46 $8.20
Average True Range (ATR) 1.84 0.25
MACD 0.07 0.00
Stochastic Oscillator 76.40 49.74

Price Performance

Historical Comparison
SCSC
GYRE

About SCSC ScanSource Inc.

ScanSource Inc is a technology distributor uniquely positioned to address complex, converging technologies and to accelerate growth for channel sales partners across hardware, SaaS, connectivity, and cloud. The Company provides technology solutions and services from suppliers of mobility and barcode, POS, payment terminals, physical security, networking, communications, connectivity, and cloud services to channel sales partners located mainly in the United States and Brazil. It has two reportable segments based on the sales model: Specialty Technology Solutions, which generates maximum revenue and includes hardware, SaaS, and subscription services through a wholesale/resale sales model, and Intelisys & Advisory. Geographically, it derives the majority of its revenue from the United States.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: